Insider Transactions in Q3 2021 at Veracyte, Inc. (VCYT)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 17
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
2,600
-1.18%
|
$130,000
$50.18 P/Share
|
|
Sep 10
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
1,900
-0.86%
|
$95,000
$50.03 P/Share
|
|
Sep 08
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
926
-1.82%
|
$46,300
$50.53 P/Share
|
|
Sep 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
12,531
-9.96%
|
$626,550
$50.88 P/Share
|
|
Sep 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,531
+6.59%
|
$200,496
$16.96 P/Share
|
|
Sep 02
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,288
-3.42%
|
$118,976
$52.97 P/Share
|
|
Sep 02
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
912
-1.76%
|
$47,424
$52.97 P/Share
|
|
Aug 02
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Indirect |
4,400
-29.22%
|
$193,600
$44.06 P/Share
|
|
Jul 19
2021
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+50.0%
|
-
|